Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06208072 Recruiting - Obesity Clinical Trials

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high. The identification of biomarkers with prognostic and predictive roles seems to play an important role in the management of hypertensive patients. Proteomic analysis studies provide encouraging results in the identification of such biomarkers. The goal of this clinical study is to is to highlight peptides through urinary proteomic analysis of obese hypertensive patients, capable of predicting blood pressure response, following treatment with irbesartan or eplerenone.

NCT ID: NCT06205628 Recruiting - Hypertension Clinical Trials

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Start date: March 21, 2024
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.

NCT ID: NCT06165250 Recruiting - Clinical trials for Essential Hypertension

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Start date: April 17, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia

NCT ID: NCT06130124 Recruiting - Clinical trials for Essential Hypertension

S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement

Start date: February 22, 2023
Phase:
Study type: Observational

Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug.

NCT ID: NCT06093932 Recruiting - Clinical trials for Hypertension,Essential

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

ESCIHP
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

NCT ID: NCT06090617 Recruiting - Hypertension Clinical Trials

Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn

WHYSKI
Start date: January 1, 2021
Phase:
Study type: Observational

WHYSKI is a prospective within-patient observational clinical study designed to test the hypothesis that alterations of Na+, K+, water, and the lympho-angiogenetic transcription factor Tonicity Enhancing Binding Protein (TonEBP) mRNA take place in the interstitium of the skin compartment of patients with arterial hypertension due to primary aldosteronism in whom hypertension can be surgically cured.

NCT ID: NCT06084065 Recruiting - Hypertension Clinical Trials

Feasibility and Effectiveness of a Ring-type Blood Pressure Measurement Device

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the feasibility and effectiveness of a ring-type blood pressure measurement device compared to a 24-hour ambulatory blood pressure monitoring device in patients with hypertension or suspected hypertension. The main question it aims to answer is whether the 24-hour blood pressure measurement accuracy of the ring-type blood pressure monitor is similar to that of the 24-hour ambulatory blood pressure monitor. To participate, subjects must wear a ring blood pressure monitor and an ambulatory blood pressure monitor simultaneously for 24 hours.

NCT ID: NCT06059638 Recruiting - Hypertension Clinical Trials

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

BACKBEAT
Start date: December 27, 2023
Phase: N/A
Study type: Interventional

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic Astra/Azure DR MRI IPG.

NCT ID: NCT06052748 Recruiting - Clinical trials for Hypertension,Essential

A Study to Evaluate the Efficacy and Safety of AD-223

Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AD-223

NCT ID: NCT06049862 Recruiting - Clinical trials for Primary Hypertension

The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial

"MaRiTensi"
Start date: October 11, 2023
Phase: N/A
Study type: Interventional

This study aims to know the effectiveness of "MaRiTensi" in improving knowledge, motivation, efficacy, self-care and blood pressure control for hypertension patients. This study hypothesizes that MaRiTensi effectively increases the knowledge, motivation, self-efficacy and self-care of hypertensive patients and reduces blood pressure in the intervention group compared to the control group. Respondent recruitment is as follows: 1. The respondent candidate will be identified based on data on record medical 2. Appropriate respondent candidates' criteria inclusion and exclusion contacted for given informed consent 3. Prospective respondents who are willing to participate and fulfill the criteria for pressure blood moment measurement will request signed consent 4. Respondents fill in the basic data and recapitulate by the assistant researcher 5. Done randomization for allocation of group interventions and group control 6. Respondents given envelope closed (using sequentially numbered, opaque sealed envelopes (SNOSE) method ) 7. Respondents' group intervention was given maintenance by Hospital or health center standard-added intervention using MaRiTensi by conditions; meanwhile, group control was provided care by Hospital or health center standards.